A Phase 1 Study Testing CP-675,206 In Combination With Gemcitabine In Patients With Previously Untreated, Advanced Pancreatic Cancer

• Status: Completed
• Trial end date: 2011-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the safety and tolerability of different doses of CP-675,206 in combination with gemcitabine and to determine the maximum dose of CP-675,206 that is well tolerated when given in combination with gemcitabine to patients with advanced pancreatic cancer.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Antibodies, Monoclonal; Gemcitabine; Tremelimumab

Criteria

Inclusion Criteria:

• Patients with metastatic pancreatic cancer

• Patient must have adequate bone marrow, liver and kidney function

• Patient must have an Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1

• Chemotherapy naive

• Inoperable pancreatic cancer

Exclusion Criteria:

• Patient must not have received prior systemic therapy for pancreatic cancer

• Patient must not have previously received anti-CTLA4 therapy

• History of chronic inflammatory or autoimmune disease